According to our new research study on "Custom Antibody Services Market Forecast to 2031 - Global Analysis - by Product Type, Service Type, Application, Source, Disease Indication, and End User," the market is expected to grow from US$ 590.33 million in 2023 to US$ 1,216.35 million by 2031; it is estimated to record a CAGR of 9.5% from 2023-2031. Key factors driving the growth of the custom antibody services market are the rising prevalence of chronic diseases and growing approvals of biosimilars. However, the high costs and complexities associated with antibody production using transgenic animals hinders the market's growth.
The scope of the custom antibody services market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. Asia Pacific is anticipated to register the fastest CAGR in the custom antibody services market from 2023 to 2031. Owing to the rise in geriatric population, increasing chronic and infectious disease prevalence, and burgeoning demand for advanced medical technologies, the market is expected to witness growth in the region. Additionally, the collaborative efforts of market players to offer more efficient custom antibody services, coupled with the rapidly growing pharmaceutical and biotechnology industries, support the growth of the custom antibody services market growth in Asia Pacific. China, India, and Japan are three significant contributors to the market growth in this region. According to the GLOBOCAN 2022 data released by the WHO, there were ~1,005,100 new cancer cases in Japan in 2022. In the same year, cancer-related mortality reached the number of 426,278. The growing geriatric population in Japan is likely to propel the demand for the development of effective treatment options, thereby creating the need for custom antibody services. According to the World Population Prospectus, published by the United Nations in 2021, Japan had one of the highest life expectancies at birth (~85 years), and at least 0.5 million people are aged 65. The study "National Institute of Population and Social Security Research, Population Projections for Japan: 2015-2065" reported that 37.7% of the Japanese population will be 65 or older by 2050.
The growing geriatric population is more prone to neurological diseases. According to the study titled "Current Status of Telemedicine for Parkinson's Disease in Japan: A Single-Center Cross-Sectional Questionnaire Survey," published in the National Library of Medicine, the prevalence of Parkinson's disease in Japan was reported to be 50-80 per 100,000 persons, and it is increasing rapidly as aging is a major risk factor for the disease. Custom antibodies can be used to identify and target proteins involved in Parkinson's disease. Antibodies targeting alpha-synuclein have been utilized to study the protein's role in the disease process and develop new treatments.
Moreover, the massive population of China, coupled with the rising incidences of various diseases, boosts the growth of pharmaceutical companies in the country. Approximately 7 people are diagnosed with cancer, and 4 people die due to cancer in China. Custom antibody services provide essential tools for developing effective cancer treatments for patients, improving diagnostic accuracy, and advancing personalized medicine approaches, supporting the custom antibody services market growth.
China is home to various medical, pharmaceutical, and biotechnology companies operating across the world. It has over ~300 medical contract research organizations (CROs) along with prominent biopharmaceutical product manufacturers. CROs utilize custom antibody services to develop highly specific antibodies for research and drug development. Custom antibodies help CROs provide precise and effective solutions for customer's specific research needs. In 2020, Bio-Thera Solutions (a Chinese biotech company) received US$ 241 million in funding from investors, including the China Life Science Fund, to support the development of its monoclonal antibodies pipeline. These antibodies are widely utilized in various applications, including drug discovery, diagnostics, and therapeutics. In March 2024, Sino Biological, Inc., which provides biological research reagents and contract research services, formed a services partnership with Toronto-based Rapid Novor, Inc. Under the agreement terms, Sino Biological would market Rapid Novor's proprietary de novo REmAb monoclonal antibody sequencing service in combination with its custom monoclonal antibody development and production services. Thus, an upsurge in funding initiatives from governments and investors, and strategic efforts by companies hold potential opportunities for the custom antibody services market growth in China.
Furthermore, major infectious diseases prevalent in India include hepatitis, AIDS, and tuberculosis. According to the WHO, India has the highest burden of tuberculosis (TB), with two deaths occurring every three minutes from TB. The country accounted for 25% of the global TB burden, with an estimated TB incidence of 2.77 million in 2022. Custom antibodies are utilized to develop new diagnostic tests, vaccines, and immunotherapies against tuberculosis. The burgeoning biotechnology and pharmaceutical industries in India fuel the demand for advanced research tools, including custom antibodies, to support drug development and research. ABGENEX is a leading company developing custom polyclonal antibodies in the country. It provides a full range of custom antibody development and production services for the life science and biotechnology industry in India. The company has well-equipped laboratories for developing polyclonal and monoclonal antibodies. It develops polyclonal antibodies from synthetic peptides, recombinant protein, gel-eluted protein, gel-embedded protein, and purified protein. The company develops these antibodies through their in-house research & development (R&D) as well as from domestic and foreign scientific collaborations, supporting the custom antibody services market growth.
Thermo Fisher Scientific Inc.; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc.; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; and Creative Biolabs Inc. are among the leading companies profiled in the custom antibody services market report.
Based on product type, the custom antibody services market is categorized into monoclonal, polyclonal hybridoma, recombinant antibody, and others. By service type, the market is segmented into antibody discovery and development, antibody production services, and others. Based on application, the market is divided into immunohistochemistry, western blot & IP, ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. In terms of disease indication, the market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others. By source, the custom antibody services market is segmented into chicken, rabbits, rats, guinea pigs, mouse or humanized mice, and others. By end user, the market is segmented into the life science industry, pharmaceutical & biotech companies, academic & research institutes, and contract research organizations. Geographically, the market is categorized into North America (the US, Canada and Mexico), Europe (France, Germany, the UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Contact UsContact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id:
sales@premiummarketinsights.com